Are peptides legal? U.S. rules by peptide and use

By Peptide Care Index

The answer to "are peptides legal" is yes for many products: approved medicines such as Wegovy are legal through prescription care, and compliant collagen and skincare products are sold legally. But BPC-157 and TB-500 have no FDA-approved product. A prescription, compounding claim or "research use only" label does not by itself make an unapproved product lawful to sell for treatment.

The rules turn on specific actions: selling, shipping, compounding, importing, passing a product to someone else, and possessing certain drugs under state law. Sport and military rules are separate checks. A July 2026 advisory vote was not a drug approval or final compounding authorization; the FDA records checked October 15 did not establish a new routine supply basis for BPC-157 or TB-500. (FDA framework; final list; federal prohibited acts).

U.S. rules only. Sources checked October 14–15, 2026. This is general information, not advice about your own legal situation.

What changes the answer for you

• The exact peptide. Semaglutide and BPC-157 are both peptides. The law treats them completely differently.
• The channel. A pharmacy prescription, a compounded prescription, a supplement or skincare product, or a vial labeled "research use only."
• What you are doing. Selling, shipping, importing and passing a product on are different from simply owning it. State possession rules and other applicable laws still matter.
• Where, and for what. Your state, a border crossing, and sport or military drug rules each add their own limits.

Jump to: Legal-status table · Product and action check · Who the law targets · Buying for yourself · "Research use only" · Importing · Prescriptions and compounding · What changed in 2026 · Sport and military · States · Questions to ask before you pay

Peptide legal-status table: 25 entries checked October 2026

This table covers 25 selected peptides and peptide groups, plus two substances often discussed alongside them. It separates approved products, specific compounding-list findings, ordinary consumer sales and sports rules. It is not a legal clearance for a seller, a patient or every possible formulation.

How to read the "prescription or compounding record" column. Each finding tests the requirement stated in that cell: an identified product approval, a final-list entry, or coverage under a specific interim category. Those are different findings—not one overall legal score.

• Supported means the cited record supports that cell's specific requirement. A Category 1 finding supports category placement, not approval or a complete lawful transaction.
• Contradicted means the cited record contradicts the particular claim being checked, such as placement on the final 503A list or inclusion in Category 1.
• Unresolved means we have not finished reviewing the basis.

These labels describe that one requirement. They are not safety ratings. You can read more in our methodology.

A few terms, defined once. Compounding means combining, mixing or changing ingredients to prepare a medicine for a particular need. Section 503A covers qualifying compounding by licensed pharmacists or physicians; 503B covers registered outsourcing facilities, not a size of pharmacy. WADA is the World Anti-Doping Agency; its rules apply to athletes covered by the relevant anti-doping rules. "Research use only" (RUO) is a label describing a claimed research purpose, not permission for human treatment. (FDA compounding explanation; WADA 2026 List).

Are peptides legal? Check the product and the action

Are peptides legal? A peptide's legal status comes from the product, its intended use and the action involved, not from being a peptide. An approved medicine and an unapproved research-labeled offer can contain a similarly named ingredient without sharing the same authorization.

A peptide is a short chain of amino acids, the building blocks of proteins. For biological-product regulation, FDA defines a protein as an alpha-amino-acid polymer with a specific sequence greater than 40 amino acids (21 CFR 600.3(h)(6)). That does not make every shorter chain a drug: foods and cosmetics still depend on their category and intended use. Biological medicines such as insulin follow a separate licensing framework; FDA says biologics are not eligible for the compounded-drug exemptions in 503A and 503B (FDA).

Four channels people commonly encounter

Two points trip people up. First, "approved" and "legal" are different questions. Approval covers one finished product. Legality also covers who sells it, how, and to whom. Second, a compounded drug can be lawful and still not be FDA-approved. FDA says plainly that compounded drugs are not FDA-approved and are not checked by FDA for safety, effectiveness or quality before they are sold (FDA compounding Q&A).

Supplements and skincare peptides are not "research drugs"

The word "peptide" on a label does not make a product illegal. A collagen powder you stir into coffee can be sold as a food or supplement. A peptide face serum can be sold as a cosmetic. FDA does not preapprove dietary supplements; cosmetics generally do not need premarket approval, apart from certain color-additive requirements. Each category still has its own rules. (FDA supplements; cosmetics).

The line that matters is intended use. FDA decides whether something is a cosmetic or a drug by what it is meant to do, judged partly by what the seller claims (FDA). A serum sold "to smooth the look of fine lines" is a cosmetic. The same serum sold "to heal wounds" is being sold as a drug.

Two boundaries matter:

• An injection is never a supplement. Supplements are taken by mouth.
• A capsule doesn't make an unapproved drug a supplement. BPC-157 capsules labeled as a supplement don't become legal, because the Defense Department's supplement-safety program states BPC-157 "is not a dietary ingredient" (OPSS). For what the oral evidence shows, see BPC-157 capsules.

If collagen or skincare was all you were asking about, you have your answer: compliant food, supplement and cosmetic products can be bought without a prescription. The word "peptide" is not a ban.

What each common claim actually proves

Sellers and clinics often answer the legal question with one reassuring fact. This table shows what each of those facts can and cannot establish.

This check is for understanding an offer or a headline. It is not a permit to buy, import, inject or compete while using a product.

Who the law targets: buyer, seller, prescriber or importer

U.S. drug law distinguishes the acts of selling, shipping, compounding, importing and passing a product on. Simply owning a product is a different question, but that does not make every purchase or possession lawful. The table separates those questions rather than estimating anyone's enforcement risk. (Federal prohibited acts; personal importation).

For violations covered by the general penalty provision of the Food, Drug, and Cosmetic Act, the stated imprisonment limit is ordinarily one year, rising to three years for a qualifying repeat conviction or intent to defraud or mislead (21 U.S.C. 333(a)). The old dollar figures printed in that section are not a reliable maximum fine: the general federal fine rules can authorize higher amounts (18 U.S.C. 3571). Penalties depend on the actual offense and facts, not simply on the word "peptide."

Can you legally buy peptides for yourself?

You can legally buy approved prescription peptide medicines through a valid prescription channel, and compliant collagen or skincare products without a prescription. For an unapproved treatment offer such as BPC-157, the seller's conduct, your import or delivery activity, and state possession rules need separate checks. A research label does not resolve any of them. (FDA human-use marketing concerns; prohibited acts).

What federal law actually prohibits

The federal Food, Drug, and Cosmetic Act lists "prohibited acts." The ones that apply here are:

• introducing or delivering an adulterated or misbranded drug into interstate commerce, or introducing an unapproved new drug in violation of the approval requirement (21 U.S.C. 331(a), (d));
• receiving an adulterated or misbranded drug in interstate commerce and delivering or offering to deliver it, for payment or otherwise (21 U.S.C. 331(c)).

In plain words, those provisions address introducing drugs into commerce and receiving them for onward delivery—not simple possession by itself. That is a narrow reading of the cited provisions, not a promise that no other federal or state offense applies. The official federal-code text retrieved for this source review is the 2024 edition; this page is not a complete check of later amendments or case law. (Section 331; section 333).

Are peptides controlled substances?

Federal scheduling and FDA drug status are different systems. An exact-name check of the selected wellness-peptide names and aliases in DEA's alphabetical controlled-substance reference did not identify those names. That is not a chemical-analogue analysis, a check of every possible peptide, or proof of what an untested vial contains. "Not found by name" also does not mean approved, lawful to sell or exempt from state drug laws.

A separate rule people miss concerns human growth hormone. It is a protein, not a small peptide, but it is often sold alongside peptides. Knowing distribution outside the medical-use and physician-order conditions in section 333(e) is a separate federal offense (21 U.S.C. 333(e)). That rule does not extend to every peptide that makes the body release growth hormone. It is specific to growth hormone itself.

State laws can reach the person who owns it

"Not a controlled substance" is a federal label. It is not your state's possession law. Some states make it a crime to have a prescription-only drug without getting it through a prescription.

A semaglutide pen is an example of a prescription product, but a person's legal position still depends on how and why they possess it and any applicable exemption. Whether a research-labeled BPC-157 vial counts as a "dangerous drug" in Texas or a "new drug" in Florida depends on legal definitions we have not applied to any particular product. These two states are examples, not a 50-state survey.

Sharing or reselling changes the legal question

Sharing or reselling can move the question from possession to delivery. The federal provision concerns receipt of an adulterated or misbranded drug in interstate commerce and delivery or offered delivery, including without payment (21 U.S.C. 331(c)); its application and any defenses require the actual facts. Texas separately regulates possession for sale (§ 483.041(b)). Florida has a third-degree-felony provision for possession with intent to sell, dispense or deliver the covered drugs (§ 499.03(3)).

If you already have a vial

A warning letter to a seller is not a charge against you. The warning letters linked in this article address the named businesses; they do not decide a buyer's individual legal position. Practical steps:

• If you have symptoms after a product, such as trouble breathing, chest pain or fainting, seek emergency care; call 911 for an emergency. A high fever with chills after an injected product also needs prompt medical attention. Bring the label if doing so does not delay care. You can report the problem to FDA MedWatch.
• Keep the records: label, order confirmation, and any prescription. Don't relabel, resell or give it away.
• If you receive an official notice, such as a customs detention or a letter from a regulator, follow the process the notice describes. For a question about your own situation, a lawyer licensed in your state is the right person.

A common situation (hypothetical)

Jordan, a hypothetical reader, ordered a "research use only" BPC-157 vial from a U.S. website for knee pain.

Are "research use only" peptides legal?

A "research use only" label does not decide whether a sale is lawful. Genuine nonclinical research supply is different from marketing an unapproved drug to consumers for treatment. FDA looks at the intended use shown by the offer, including health claims, directions and associated supplies—not just a disclaimer (FDA).

FDA's current unapproved-GLP-1 page describes illegally sold semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products carrying research or nonconsumption labels while being sold to consumers for human use with dosing instructions (FDA, updated October 1, 2026).

What FDA looks at is the whole offer, not the footer. It looks at treatment claims, human dosing directions, and what else the seller ships with the product. Our selected register contains 18 FDA warning letters dated February 7, 2024 through August 24, 2026. Within that disclosed set—not all FDA peptide enforcement:

• 11 letters cite water or injection supplies as evidence the product was meant for people.
• In 9 of the 11 letters issued in 2026, FDA also called the water or "reconstitution" product itself an unapproved drug.
• The register records semaglutide in 14 letter-product records, retatrutide in 13 and tirzepatide in 11. These are normalized mentions in the specified product records, not a count of products bought or patients exposed.

Full details and the coding rules are in the register and its water-product finding. Warning letters state FDA's findings in dated reviews; they are not court judgments or proof of a company's present status.

A purity certificate doesn't change the legal answer. A certificate of analysis documents the tests actually reported on the identified sample. An advertised purity percentage alone does not show:

• that your vial matches the sample;
• that the product is sterile or safe to inject;
• that it works;
• that anyone may legally sell it to you.

For what independent testing of peptide products has found, see peptide purity testing statistics.

Authorized human research is a different thing from a research vial. Investigational products can have authorized routes that do not involve ordinary retail treatment sales. Two examples are:

• Authorized clinical investigations. A U.S. study must meet the applicable requirements, including an investigational new drug application in effect when required and the relevant human-subject protections. Listing on ClinicalTrials.gov is not that authorization (21 CFR 312.40).
• FDA's expanded access program, sometimes called "compassionate use." It is a potential pathway for a patient with a serious or immediately life-threatening condition to receive an investigational product outside a trial, when no comparable treatment is available (FDA).

Neither one is a way to buy a vial online for general wellness. A study listing also isn't proof that a study is enrolling; only the study team can confirm that.

Can you import peptides for personal use?

For an unapproved drug ordered for your own treatment, personal importation is generally unlawful. FDA can exercise enforcement discretion in limited circumstances; that is not a general legal exemption. The answer for a compliant food or cosmetic is different. A small order, foreign prescription or research label does not settle the import requirements (FDA).

FDA's personal-importation guidance and Regulatory Procedures Manual, chapter 9-2 describe case-specific discretion. The guidance has a branch for a nonserious condition where the product does not pose a significant health risk, and a branch for serious conditions with the factors below. Neither creates a right to import a wellness drug.

The "90-day supply" claim misses the point. The guidance generally refers to a three-month quantity within a conditional policy, not a right to import an unapproved drug.

An overseas seller accepting your payment shows only that it accepts your order. It does not show that the shipment meets U.S. import rules. That's our reading of how the rules fit together, not a finding about any named seller. If a shipment is detained, the notice will describe the process to follow. If you need advice about your own case, speak to a lawyer.

Does a prescription make any peptide legal?

No. A prescription does not give an unapproved product FDA approval or remove the rules on compounding. Clinicians generally can prescribe approved drugs off-label when medically appropriate, but other restrictions can apply. For the July-review peptides, the current final-list and Category 1 records checked here did not supply the claimed compounding basis. A complete offer-specific basis is a separate question (FDA 503A framework).

Off-label prescribing starts with an approved drug

"Off-label" means using an approved drug in a way its label does not describe. FDA explains that this can be appropriate when a doctor judges it medically right (FDA). The starting point is always an approved product. A doctor cannot turn BPC-157 into an approved medicine by writing a prescription, because no approved BPC-157 product exists. The useful question to ask is simple: which approved product do you mean?

Compounding has conditions, not a peptide exemption

A compounded medicine is prepared by combining, mixing or changing ingredients, rather than supplied as that approved finished product. The two federal compounded-drug frameworks differ; neither one is a blanket exemption for peptides.

An eligible ingredient is only one condition. For bulk ingredients, FDA also identifies manufacturer-registration and valid certificate-of-analysis requirements; applicable quality standards and the other compounding conditions still matter. A certificate can be required without being proof of approval or of a lawful finished preparation (FDA assessment explaining the statutory conditions).

FDA's three interim categories, in plain words:

• Category 1. Nominated with enough information for review and covered by a conditional policy of not taking specified enforcement action while FDA evaluates the substance. The policy requires more than being on the list; it is not drug approval or a new statutory exemption.
• Category 2. FDA has identified significant safety risks. FDA says it "would consider taking action" against a pharmacy compounding with these.
• Category 3. Nominated without enough information. Not covered by the interim policy.

Source: FDA 503A page.

FDA's final 503A list is very short. When we checked the version current through October 13, 2026, it named six substances, and none was a peptide from our table (21 CFR 216.23).

Where the popular peptides sit today

In April 2026, BPC-157, TB-500 and other peptides left Category 2 after their nominations were withdrawn. Contemporary reporting described an April 15 notice and removal seven days later (Orrick). The current FDA category file and withdrawn-nomination table establish the displayed classification—not that safety concerns disappeared. Leaving Category 2 was not a move into Category 1.

• The seven July-review peptides are absent from the current 503A category file; they did not move into Category 1.
• Those seven peptides are not on the displayed final 503A list.
• FDA's 2026 staff briefings reported no approved-drug component or applicable USP/NF monograph for the free base and acetate forms it reviewed. That is a dated agency finding, not an independent search of all later USP/NF updates.
• This check did not locate a subsequently announced operative FDA policy covering their routine compounding. The search covered the cited FDA framework, category files, meeting materials and relevant official-agency results; it does not certify every possible source or transaction.

USADA, the U.S. anti-doping agency, gives the same warning about BPC-157: "Currently, there is no legal basis to include BPC-157 in any compounded medication" (USADA).

The rest of the picture:

• Still in Category 2: kisspeptin-10.
• Category 3: GHRP-2 and GHRP-6.
• Category 1: glutathione, vasoactive intestinal peptide (VIP), alanyl-L-glutamine, and GHK-Cu for non-injected routes only.

The full entries are in our FDA peptide compounding list.

Compounded GLP-1s (semaglutide and tirzepatide)

During the injection shortages, some restrictions on compounding copies were relaxed; other conditions still applied. FDA has since declared both injection shortages resolved (current policy explanation). This does not mean every individualized compounded prescription is automatically unlawful. Under 503A, a prescriber-determined and documented change producing a significant difference for an identified patient can matter; the rest of the requirements still apply. Adding an ingredient or calling a product personalized is not enough by itself.

On February 6, 2026, FDA announced action against mass-marketed compounded GLP-1s and misleading claims that they are generic or the same as approved drugs (FDA announcement). On April 30 it proposed excluding semaglutide, tirzepatide and liraglutide from the separate 503B bulks list (proposal); the inspected announcement is a proposal, not a final determination. Retatrutide is different again: FDA expressly says it cannot be used in compounding under federal law (FDA).

Sermorelin and other clinic offers

Some clinics advertise compounded sermorelin through licensed pharmacies. The historical Geref approval is real, and FDA's later determination that it was not withdrawn for safety or effectiveness is important (FDA notice). Those records do not establish every condition for a current compounded offer. We mark that offer-specific requirement Unresolved. Ask which exact ingredient basis and other conditions the named pharmacy relies on.

How to tell whether a clinic's peptide offer has a legal basis

1. Which exact peptide and form (for example, free base or acetate), and which route: injection, capsule, cream or nasal?
2. Is it an FDA-approved product or compounded?
3. If it's compounded, which pharmacy makes it, and which 503A or 503B framework, ingredient-specific record and other conditions support that form and route?
4. Is the pharmacy licensed to ship to your state?
5. Is the prescriber licensed where you will be during the appointment?
6. What happens to your money if no prescription is written or the pharmacy can't fill it?

For BPC-157 specifically, see how BPC-157 access routes work and what FDA records say about its approval status.

Did peptides become legal again in 2026?

There was no blanket "peptides are legal again" decision. In 2026, FDA changed nomination records and an advisory panel reportedly recommended six peptides for the 503A list. The final regulation checked October 15 still did not include those peptides. A reported temporary policy is not an operative agency action; no replacement policy was located in this check. (Current category file; final regulation; nonbinding advisory role).

What changed, and what didn't

Why "removed from the list" isn't "allowed"

Think of an application withdrawn from a review queue. It has not become a permit. Leaving Category 2 after a nomination is withdrawn does not put the substance in Category 1, add it to the final list or approve it. FDA still discusses potential safety risks for these substances in its withdrawn-nomination table.

Two different developments could change the compounding discussion; they would not have the same legal effect:

• A final 503A list change. FDA could add a defined substance through rulemaking. That could satisfy the list condition for that substance, but all other applicable compounding requirements would remain.
• An operative enforcement-discretion policy. FDA could state conditions under which it would not take specified enforcement action. That is not drug approval, does not amend the statute, and does not bind state regulators. The actual document—not a report about a plan—would determine its scope.

Neither development would automatically change these separate checks:

• A compounded BPC-157 would still not be an FDA-approved drug.
• A research label would still not supply authorization for consumer treatment sales; the actual product and applicable rules would have to support the sale.
• FDA action would not itself amend WADA's List; athletes would need to check the operative sports rules.

For the latest dated BPC-157 records, see BPC-157 news and FDA updates.

Is a legal peptide a safe one?

No. Legal and safe are separate questions. FDA approval means FDA has reviewed the submitted evidence for a defined finished product and use; it is not a promise of no risk. Compounded drugs do not undergo the same FDA premarket approval review, and a research label is not that review either (FDA).

Glutathione shows the gap. Glutathione is listed in Category 1 under FDA's conditional 503A enforcement policy. Even so, FDA described reports involving at least 30 patients after IV glutathione, alone or in combinations, prepared from supplement-grade material; the alert also describes pharmacy recalls (FDA, August 27, 2026). Those reports are not a measured risk rate or proof that glutathione caused every event. The lesson for an injected product is to ask about the exact ingredient's suitability for sterile preparation and the finished product's quality controls—not just whether the ingredient appears on a list.

FDA has flagged concerns about the unapproved ones. For BPC-157 and the TB-500 fragment, FDA describes possible immune reactions for some routes, peptide-related impurities, and little human safety information (FDA safety-risk page). FDA's evidence on TB-500 concerns the specific fragment. It should not be confused with research on full-length thymosin beta-4 (TB-500 human evidence).

If you have a reaction, get medical care first, then report it to FDA MedWatch. Reported side effects are collected in our peptide side effects chart, peptide recalls and peptide adverse event reports.

Are peptides legal for athletes and service members?

Many peptides are banned in sport even when a doctor could legally prescribe them. BPC-157 is prohibited at all times under WADA's "non-approved substances" category, and it is on the Defense Department's prohibited supplement ingredient list. Sport and military rules are separate from U.S. drug law.

Sources: WADA's 2026 Prohibited List, effective January 1, 2026, and 2026 Monitoring Program, read October 15, 2026; see our peptide crosswalk for navigation. Prohibited classes include unnamed related substances, so absence of a name is not permission.

A prescription is not permission in sport. Ask your anti-doping organization whether a Therapeutic Use Exemption is required for your substance and competition level; a prescription alone is not one. USADA provides a TUE and pre-check process. Emergency treatment comes first—do not delay care for a TUE application. For service members, Operation Supplement Safety lists BPC-157 on the Defense Department's prohibited supplement ingredients list under DoD Instruction 6130.06 (OPSS).

Are peptides legal in every state?

Federal rules on approval, compounding and selling apply in every state. A state permission does not remove applicable federal approval or supply requirements. States add their own rules on pharmacies, prescribers, telehealth and, in some cases, owning prescription drugs.

What states control:

• Pharmacy licenses, including whether an out-of-state pharmacy may ship to you.
• Prescriber licenses. A telehealth appointment takes place where you are located at the time, so the clinician generally needs to be licensed there (HHS).
• State food and drug laws, including possession rules like those in Texas and Florida.
• Consumer-protection actions by state attorneys general.

"We ship to your state" is a delivery promise, not a license check. Ask for the clinician's name and the dispensing pharmacy, not just the website's brand.

We don't rank states as "permissive" or "strict." The two state examples here come from their statutes, not a nationwide ranking.

What to ask before you pay for peptide care

Ask for the exact product, the legal route being claimed, who is supplying it, and the full payment terms, in writing. A good answer names a record you can check, not just "prescription," "licensed" or "research grade."

Copy this product-and-access request

You don't need to argue about whether "peptides" are legal in general. Ask about the exact product you would receive and the basis for supplying it to you.

Before I pay, please send:

1. The exact product and ingredient name, including any salt or fragment, the dosage form, the route (injection, capsule, cream or nasal), the strength and the quantity supplied. Please say whether it is an FDA-approved finished medicine, a compounded preparation or an investigational product.
2. If it is an approved medicine: the manufacturer and the FDA approval record that matches this exact product, not a different product with a similar ingredient.
3. If it is compounded: the name of the dispensing pharmacy or outsourcing facility, whether it is made under section 503A or 503B, and the current basis you rely on for this exact ingredient, form and route, with the source and its date.
4. The clinician's name, and the basis for providing care where I will be located during the appointment; and the pharmacy's authorization to dispense or ship to me.
5. Whether any "research use only" label applies to the product I would actually receive, and how that fits the care you are offering.
6. The amount due today; the separate charges for consultation, medication, lab tests, membership, shipping and follow-up; how often I am billed; what renews automatically; and any minimum commitment.
7. What is refundable if no prescription is written, the pharmacy cannot fill it, or the access route turns out to be unavailable, and how to cancel.
8. Anything you cannot yet confirm, and what record or event would settle it.

This is a request for facts. A seller's answer is not proof of compliance on its own, but it tells you what to check, and a missing answer tells you something too. A charge they don't list is unknown, not zero.

Worked example: three reassuring claims, still missing the answer

Hypothetical offer, not a real provider: "BPC-157 capsules, doctor prescribed, prepared by a licensed pharmacy, 99% purity." No price is given, so we don't invent one.

Three reassuring phrases, but they do not supply the missing approval or list coverage. That's the value of checking each claim separately rather than treating them as one overall "yes." If an offer names a different peptide, the same questions work. Check that exact form and route; do not transfer BPC-157's findings to it.

Now you know which facts an offer is missing. Find My Peptide Path keeps these questions together with a fee checklist covering consultation, medication, labs, membership, shipping, renewals and refunds. You can see what an offer leaves out before you pay, and copy or print the questions for the clinic.

Find My Peptide Path

How we checked this page

We reviewed the linked government records, relevant statutory provisions and the named reports behind the findings below. This was editorial source review, not a legal, clinical or pharmacy review. We did not test a product or contact a provider. Source vintages and access limits are disclosed below.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

What the finding labels mean

• Supported: the cited record shows the stated requirement is met.
• Contradicted: the cited record shows it is not met.
• Unresolved: information we need is missing, or we have not finished the review.
• Not applicable: that requirement doesn't govern this kind of product.
• Conflicting: sources disagree and we show both. No finding on this page needed this label.

Read more in our methodology, editorial standards and how we make money. AI tools assisted with drafting, record retrieval and editing; that assistance is not a professional review.

Your next step

If the peptide you're considering is FDA-approved, your next step is a prescription conversation with a licensed clinician. If it isn't, your next step is finding out whether anyone can legally supply it to you, before money changes hands.

There are other next steps that don't involve us:

• A notice from customs or a regulator: follow the process it describes, and get advice from a lawyer in your state.
• A tested athlete: your anti-doping organization makes the call.
• Collagen or skincare: you can stop here once the product fits the applicable food, supplement or cosmetic rules. No prescription is needed for a compliant nondrug product.

Have an offer you're still trying to understand? Find My Peptide Path gives you the dated U.S. access evidence for BPC-157, TB-500 and sermorelin, a checklist for any provider's offer and fees, and questions you can copy or print. It's free and needs no account or email. It cannot approve a product, confirm your eligibility, or recommend a peptide or a dose.

Find My Peptide Path

Questions people also ask

Is it illegal to buy BPC-157? A BPC-157 consumer-treatment offer needs an applicable lawful basis; a research label does not provide one. The cited federal introduction/delivery provisions do not describe simple possession alone, but that is not nationwide legal clearance. Importation, onward delivery, state drug definitions, and sport or military rules remain separate checks. See the buyer example.

Will BPC-157 become legal? A product approval, an applicable compounding-basis change or a new enforcement policy could change different parts of the answer. None should be inferred from an advisory vote. The final-list and Category 1 records checked October 15 do not list BPC-157; no operative replacement policy was located. Enforcement discretion would not itself legalize all compounding or change WADA rules. See the dated timeline.

Is it legal to sell peptides? Approved prescription peptide medicines must move through lawful supply and dispensing channels; licensed pharmacies are not the only possible authorized dispensers. Compliant food, supplement and cosmetic products have different rules. A research label does not authorize consumer treatment sales of an unapproved drug (FDA compounding/access explanation; Texas dispensing rules).

Is PT-141 legal? The identified FDA-approved product, bremelanotide acetate (Vyleesi), is legal by prescription through an authorized channel (FDA product record). An online PT-141 vial does not inherit that approval. FDA named PT-141 offers as unapproved human-use drugs in its August 2026 warning letters.

Can I travel with peptides? For domestic travel, keeping lawful prescription medicine with its pharmacy label and prescription documentation can help explain what it is, but check the relevant state and carrier requirements. Airport screening is not a ruling that a substance is lawful to possess. Crossing a border adds U.S. import rules and the destination country's laws; a research label is not treatment or import authorization (FDA personal-importation guidance).

Are peptides legal in Canada, the UK or Australia? Rules differ by country. This page covers the United States only.

Sources and check dates

The source review below was performed October 15, 2026. A review date is not a new publication date for the source, a new effective date for a rule, or a fresh search of every database. Staff assessments, historical letters and statutory editions retain the limits stated beside them.

1. FDA — BPC-157 briefing. July 23–24, 2026 advisory materials; May 11, 2026 staff evaluation. Approval/monograph statement, PDF page 9, inspected as text and image. Covers the free base and acetate; staff analysis is not a final decision or an independent October USP/NF search.
2. FDA — TB-500 briefing. July 2026 materials. Approval/monograph statement, PDF page 7; N-acetylated Ac-LKKTETQ versus full-length thymosin beta-4 and nonacetylated fragment, PDF page 25; relevant pages inspected as text and images.
3. eCFR — 21 CFR 216.23. Displayed currency through October 13, 2026. The six entries in subsection (a) were counted; the July-review substances were not listed. This is the final 503A list, not every possible statutory ingredient basis.
4. FDA — 503A bulk-substance framework. Monograph/approved-component/final-list hierarchy and conditional interim policy; current page read. Nomination or Category 1 placement is not finished-product approval.
5. FDA — 503A category file. May 14, 2026 edition, all seven pages inspected. GHK-Cu route qualifier and withdrawal clarification, pages 1–2; glutathione and other Category 1 entries; Category 2 and 3 entries. The file date remains May 14.
6. FDA — Bulk-substance safety and withdrawn-nomination record. Exact entries and route-specific concerns read. Withdrawal is not a finding that the safety concerns vanished.
7. FDA — July 23–24, 2026 advisory meeting. Agenda, linked materials and nonbinding advisory role checked. No official vote-count record was established from the materials retrieved; the article attributes reported tallies separately.
8. FDA — Concerns with unapproved GLP-1 drugs. Page updated October 1, 2026. Retatrutide compounding statement, research-labeled consumer-treatment sales and exact-product distinctions read. The update date is not treated as the date every restriction began.
9. FDA — Action against non-FDA-approved GLP-1 drugs. February 6, 2026 announcement; enforcement and misleading-marketing statements read. Not a replacement for the compounding statutes.
10. FDA — Proposed 503B exclusion of semaglutide, tirzepatide and liraglutide. April 30, 2026 proposal. The linked notice is not a final determination; a later final action needs its own record.
11. FDA — Semaglutide injection shortage order, tirzepatide injection shortage order, and current compounding-policy clarification. Historical orders and current framework reviewed. The clarification explains the patient-specific significant-difference provision and separate 503B requirements; shortage resolution is not a blanket ban on every individualized 503A prescription.
12. FDA — Supplement-grade glutathione injectable alert. August 27, 2026. At least 30 reported patients after IV products, alone or in combinations; supplement-grade ingredient and pharmacy recalls. Not an incidence study or proof of causation in every report.
13. FDA — Compounding questions and answers. No FDA finished-product approval for compounded preparations; section 503A/503B exemptions do not apply to biological products. A separate policy on mixing/diluting/repackaging approved biologics is not a blanket peptide-compounding authorization.
14. FDA — Cosmetic, drug or both and dietary-supplement overview. Intended use, distinct product categories, qualified supplement claims and premarket-review limits. These are not approvals of named consumer products.
15. FDA — Off-label use of approved drugs. General explanation read; an approved product is the starting point. Other restrictions, including the specific hGH provision, remain relevant.
16. FDA — Expanded access; eCFR — 21 CFR 312.40. Authorized investigational routes and IND/human-subject requirements. No particular trial's enrollment, recruitment or patient availability is claimed here.
17. FDA — Personal importation. Full guidance read, including nonserious- and serious-condition branches, the three-month factor, treating-doctor/continuation-abroad alternatives and visitor guidance.
18. FDA — Regulatory Procedures Manual, chapter 9. March 2024 edition, personal-importation section 9-2; PDF pages 23–24 read as text and images. Enforcement discretion is not a legal entitlement. This direct agency source replaces reliance on the supplied CRS search excerpt.
19. FDA product records — Wegovy injection, NDA 215256, Ozempic, NDA 209637, Rybelsus, NDA 213051, Mounjaro, NDA 215866, Zepbound, NDA 217806, Vyleesi, NDA 210557, tesamorelin, BLA 022505, and Scenesse, NDA 210797. Product identity, approval/marketing records and route reviewed. The brand records do not authenticate a research vial or a compounded preparation.
20. Official U.S. Code, 2024 edition — 21 U.S.C. 331, 21 U.S.C. 333, and 18 U.S.C. 3571. Relevant provisions read directly. The current House-code section endpoints returned a temporary-site/page-not-found response; this is not a complete verification of later amendments or case law. Nominal fine figures in section 333 are not represented as the applicable maximum fines.
21. Texas Legislature — Health and Safety Code chapter 483. Definitions and sections 483.041–.042, including lawful channels and exceptions, read directly. The official site reports currency through the 89th Legislature's second called session, 2025. No particular research vial was classified under this law.
22. Florida Legislature — Section 499.03. Displayed 2026 statute; possession, intent-to-deliver/sell penalties and exceptions read. Not a 50-state legal opinion or a product-specific classification.
23. eCFR — 21 CFR 600.3(h)(6). Specific alpha-amino-acid polymer/protein definition read. Chain length alone does not make every shorter peptide a drug.
24. USADA — BPC-157 risks and sports status and Therapeutic Use Exemptions. Agency commentary distinguished from FDA legal authority. TUE requirements depend on substance and competition level; emergency care is not delayed for an application.
25. Operation Supplement Safety — BPC-157. April 29, 2025 article, read directly. Dietary-ingredient statement and Department of Defense prohibited-supplement reference; not a new October 2026 rule.
26. FDA — Musclepower Enterprise warning letter. December 12, 2025. FDA's ibutamoren dietary-supplement exclusion and unapproved-product findings; letter-specific findings, not a clinical study.
27. HHS — Licensing across state lines. Patient-location and authorized practice pathways checked. Shipping availability is not a clinician or pharmacy license check.
28. ABC News — BPC-157 advisory vote. July 23, 2026 reporting, read as reporting: 8–6 with one abstention. Not an official vote record or final agency action.
29. Pharmaceutical Executive — Four peptide recommendations. July 24, 2026 report, read for its attributed tallies. Its interpretation of categories is not used as legal authority.
30. NCPA — Six peptide recommendations. July 31, 2026 report; Semax and Epitalon recommendations reported without a verified tally in this article.
31. AJMC — Panel backs six peptides. July 31, 2026 report; emideltide tally reported as six yes, seven no and one abstention. The article does not represent this as a form-by-form official roll call.
32. Orrick — April peptide nomination changes. April 16, 2026 law-firm account of the April 15 notice and earlier remarks. The original April notice's full archived text was not recovered in this review; current FDA category records separately support the classifications used here.
33. Becker's Hospital Review — Reported HHS stopgap. October 8, 2026 article summarizing The Washington Post's October 7 report. A reported plan is not an operative enforcement policy or permission to sell.
34. Frier Levitt — Potential peptide enforcement-discretion policy. October 14, 2026 analysis read; describes a potential policy. Used for the report's status, not as a substitute for an FDA action.
35. Eli Lilly — Retatrutide phase 3 and submission-plan release. July 23, 2026 release read directly. Planned Q1 2027 BLA submission, not an actual filing, approval or guaranteed treatment-access date. This primary source replaces the supplied secondary filing attribution.
36. Peptide Care Index — Warning-letter register, compounding records, WADA crosswalk, approved-peptide list and hearing tracker. Live pages read for their records, declared selection/coding rules, neighboring ownership and usable links. Underlying FDA and WADA records were consulted for the consequential findings; linked-site update dates are not reassigned by this article's review.
37. FDA — Remaining July 2026 staff assessments: emideltide, Epitalon, KPV, MOTS-c, and Semax. Exact ingredient identities and introductory approval/monograph statements read. They do not substitute for an independent search of subsequent USP/NF changes or an official final decision.
38. FDA — CJC-1295 assessment, ipamorelin assessment, and AOD-9604 assessment. 2024 staff reviews. Form-specific approval/monograph statements; the ipamorelin and AOD introductory pages were also inspected as images. No personal dosing or route-conversion instructions are drawn from them.
39. FDA — 503B framework, 503B categories file and 503B bulks list. Distinct statutory/interim pathways read; category PDF edition March 21, 2025. Ipamorelin acetate's Category 2 entry is not transferred to another substance or to 503A.
40. FDA/Federal Register — Geref withdrawal determination. March 4, 2013 notice. Approvals withdrawn effective June 18, 2009; FDA determined the products were not withdrawn for safety or effectiveness. Historical evidence does not approve a current compounded product.
41. DEA — Alphabetical controlled-substance reference. Selected names and aliases checked in the retrieved reference. No complete chemical-analogue, mixture or state-scheduling analysis; a current publication-date label was not established from the response.
42. WADA — 2026 Prohibited List and 2026 Monitoring Program. Operative 2026 documents read as text; relevant classes and semaglutide/tirzepatide monitoring checked. PDF-image rendering was unavailable in this retrieval. “Not in our crosswalk” is not permission under a nonexhaustive class.
43. FDA — Next peptide advisory meeting. Agency page describes a meeting before the end of February 2027 and names five substances. No specific date, final recommendation or access change is invented.
44. Official U.S. Code, 2024 edition — 21 U.S.C. 321(ff). Dietary ingredients, ingestion, labeling and the drug/investigational exclusion read with FDA's current public explanations; the same statutory-edition limitation as source 20 applies.
45. FDA — MedWatch. Official reporting resource checked. Reporting does not replace care; no medical details are requested by Peptide Care Index.
46. Peptide Care Index — Find My Peptide Path, methodology, author page, editorial standards and commercial disclosure. Current public content checked for the tool's actual scope, free/no-account/no-email access, attribution, method and AI-assistance disclosure. Copy/print controls were present; their browser execution was not tested during this editorial review.